Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
Add more filters










Publication year range
1.
J Craniofac Surg ; 2024 Jul 05.
Article in English | MEDLINE | ID: mdl-38968026

ABSTRACT

OBJECTIVE: Cephalic Index (CI), the ratio of head width to length, is one of the indexes reflecting cranial morphological characteristics. Current norms were established by European and American countries. The purpose of the study was to study anthropometry of cranial parameters using computed tomography scans to establish the CI of the sampled Chinese Children. METHODS: The cross-sectional study was carried out on patients of age younger than 14 years old at Shanghai Children's Medical Center. The measurement of maximum cranial breadth and maximum cranial length were taken on a computed tomography scan machine and recorded for analysis. Cephalic Index was calculated for each age and sex group and compared with previously established norms. RESULTS: Five hundred eighteen patients met the inclusion criteria, including 301 males and 217 females. The means for boys and girls were 87.1 (SD: 4.3) and 85.8 (SD: 4.3), respectively. There was a significant difference between boys and girls (P < 0.01). Cephalic Index in different ages and on applying the 1-way analysis of variance association was statistically insignificant (P = 0.19). CONCLUSIONS: Chinese head shape was brachycephalic. A statistically significant correlation was seen between the CI and sex, while not age.

2.
Transl Pediatr ; 12(12): 2213-2221, 2023 Dec 26.
Article in English | MEDLINE | ID: mdl-38197103

ABSTRACT

Background: The goals of operative treatment for unilateral coronal synostosis (UCS) are to improve appearance and allow unrestricted brain growth. However, for severe unilateral premature closure of the coronal suture, existing methods do not address the compression of the brain or expand the volume of the skull cavity. We report our retrospective experience with bilateral fronto-orbital advancement combined with cranial vault release using a free-floating bone flap (CVR + FFBF) technique and the resulting changes in the anterior cranial vault asymmetry index (ACVAI) and intracranial volume. Methods: Twenty patients with UCS who underwent bilateral fronto-orbital advancement combined with CVR + FFBF technique from April 2014 to May 2019 were included. Surgical efficacy was evaluated by the ACVAI and intracranial volume before the operation, 1 week after the operation, and at the last follow-up (average 19.8 months; range, 12 to 40 months). The measurement data are presented as the mean ± standard deviation and were statistically analyzed by t-test. Results: The ACVAI was 9.07%±3.55% before the operation, 3.56%±3.42% 1 week after the operation, and 3.13%±2.41% at the last follow-up. The ACVAI 1 week after the operation was significantly lower than that before the operation (t=4.827, P<0.001). There was no significant difference between the ACVAI 1 week after the operation and at the last follow-up (t=0.660, P=0.517). The intracranial volume was 1,027.85±112.25 mL in patients before the operation and 1,131.92±161.71 mL in the normal control group, which was a statistically significant difference (t=2.364, P=0.023). The intracranial volume significantly increased 1 week after surgery: 1,081.62±111.10 mL (t=8.703, P<0.001), and this trend continued at the last follow-up (1,386.90±119.30 mL) similarly to the normal control group (1,438.22±89.28 mL). At the last follow-up, there was no significant difference between the two groups (t=1.540, P=0.132). Conclusions: For the treatment of UCS, bilateral fronto-orbital advancement combined with CVR + FFBF technique offers functional and cosmetic outcomes in terms of intracranial volume expansion and fronto-orbital symmetry.

3.
Int J Clin Exp Med ; 8(8): 13127-35, 2015.
Article in English | MEDLINE | ID: mdl-26550235

ABSTRACT

Tectonic family member 1 (TCTN1) encodes a member of the tectonic family which are evolutionarily conserved secreted and transmembrane proteins, involving in a diverse variety of developmental processes. It has been demonstrated that tectonics expressed in regions that participate in Hedgehog (Hh) signaling during mouse embryonic development and was imperative for Hh-mediated patterning of the ventral neural tube. However, the expression and regulation of tectonics in human tumor is still not clear. In this study, shRNA-expressing lentivirus was constructed to knockdown TCTN1 in medulloblastoma cell line Daoy. The results showed that knockdown of TCTN1 inhibited cell proliferation and colony formation in Daoy cell line, also caused cell cycle arrest at the G2/M boundary. Taken all together, our data suggest that TCTN1 might play an important role in the progression of medulloblastoma.

4.
Mol Med Rep ; 11(5): 3337-43, 2015 May.
Article in English | MEDLINE | ID: mdl-25571951

ABSTRACT

Spliceosome mutations have been reported in various types of cancer and a number of antitumor drugs have been observed to tightly bind to spliceosome components. Small nuclear ribonucleoprotein­associated polypeptide N (SNRPN) is a small ribonuclear protein and is a key spliceosome constituent. However, the role of SNRPN in human medulloblastoma remains unknown. In the present study, the effect of SNRPN on cell growth was investigated in vitro using the Daoy human medulloblastoma cell line. Lentivirus (Lv)-mediated short hairpin (sh) RNA was used to silence SNRPN expression, which was verified by reverse transcription­quantitative polymerase chain reaction and western blotting. Cell proliferation was examined by MTT and colony formation assays. Knockdown of SNRPN markedly reduced the proliferation and colony formation ability of Daoy medulloblastoma cells. In addition, flow cytometric analysis revealed that the cell cycle distribution was altered when the Daoy cells were infected with Lv­shSNRPN. To the best of our knowledge, this is the first study to investigate the effect of SNRPN on cell proliferation in medulloblastoma. The results indicate that SNRPN may be a potential novel target for the development of pharmacological therapeutics in human medulloblastoma.


Subject(s)
Medulloblastoma/genetics , snRNP Core Proteins/genetics , Cell Cycle/genetics , Cell Line, Tumor , Cell Proliferation , Gene Expression , Gene Expression Profiling , Gene Knockdown Techniques , Humans , Medulloblastoma/metabolism , RNA, Small Interfering/genetics , Tumor Stem Cell Assay , snRNP Core Proteins/metabolism
5.
Biotechnol Appl Biochem ; 62(6): 868-73, 2015.
Article in English | MEDLINE | ID: mdl-25524330

ABSTRACT

Medulloblastoma is the most common malignant pediatric brain tumor in children. GPR137 is a ubiquitously expressed gene in the central nervous system. It has been reported that GPR137 modulates malignant proliferation of glioma cells. However, the relationship between GPR137 and medulloblastoma is still unknown. In this study, we knocked down GPR137 in the medulloblastoma cell line Daoy via a lentivirus-based RNA interference system to explore its role in medulloblastoma. Functional analyses showed that cell proliferation and colony formation were obviously restrained in Daoy cells after GPR137 knockdown. Furthermore, knockdown of GPR137 in Daoy cells led to a significant increase in cell percentage in the G0/G1 phase but a decrease in the S phase. Additionally, the cell population in the sub-G1 phase, which represents apoptotic cells, was remarkably increased in GPR137 knockdown cells. GPR137 inhibition induced a strong proapoptotic effect in Daoy cells, as confirmed by annexin V-APC/7-AAD double staining. In conclusion, GPR137 knockdown inhibited growth of Daoy medulloblastoma cells via disturbing cell cycle progression and inducing apoptosis. Our investigation suggested that GPR137 could be a potential oncogene in medulloblastoma cells and might serve as a target for the treatment of medulloblastoma.


Subject(s)
Cerebellar Neoplasms/pathology , Gene Knockdown Techniques , Gene Silencing , Medulloblastoma/pathology , Receptors, G-Protein-Coupled/deficiency , Receptors, G-Protein-Coupled/genetics , Apoptosis/genetics , Base Sequence , Cell Cycle/genetics , Cell Line, Tumor , Cell Proliferation/genetics , Cell Survival/genetics , Humans , Lentivirus/genetics , RNA, Small Interfering/genetics
6.
Neurol Med Chir (Tokyo) ; 53(1): 47-52, 2013.
Article in English | MEDLINE | ID: mdl-23358171

ABSTRACT

Extensive multilobar cortical dysplasias occasionally occur in children and can induce seizure onset in early infancy, causing severe epileptic encephalopathy. Surgical interventions in early infancy, such as disconnection of large parts of the brain, are challenging because of the degree of invasiveness and carry greater risks in infants compared with older children. Here we report the successful treatment of intractable epilepsy with multilobar cortical dysplasias in the posterior cortex by posterior disconnection in three infants (age 3 months). The patients showed good postoperative recovery and exhibited excellent seizure control at follow-up evaluation within a year after surgery. Developmental catch-up was also achieved and no early complications have been detected to date. Use of the posterior disconnection technique for early-stage extensive multilobar cortical dysplasias can result in good seizure control and developmental progress with little perioperative morbidity. However, the efficacy of this surgical technique needs to be verified with long-term follow up after surgery.


Subject(s)
Anterior Temporal Lobectomy/methods , Epilepsy, Tonic-Clonic/surgery , Malformations of Cortical Development/surgery , Spasms, Infantile/surgery , Cerebral Cortex/pathology , Electroencephalography , Female , Follow-Up Studies , Humans , Image Interpretation, Computer-Assisted , Imaging, Three-Dimensional , Infant , Magnetic Resonance Imaging , Male , Malformations of Cortical Development/diagnosis , Postoperative Complications/diagnosis , Reoperation , Spasms, Infantile/diagnosis , Subtraction Technique , Tomography, Emission-Computed, Single-Photon
7.
PLoS One ; 8(12): e84723, 2013.
Article in English | MEDLINE | ID: mdl-24386409

ABSTRACT

Astrocytoma cells characteristically possess high invasion potentials. Recent studies have revealed that knockdown of signal transducers and activators of transcription 3 (STAT3) expression by RNAi induces apoptosis in astrocytoma cell. Nevertheless, the distinct roles of STAT3 in astrocytoma's invasion and recurrence have not been elucidated. In this study, we silenced STAT3 using Small interfering RNAs in two human glioblastoma multiforme (GBM) cell lines (U251 and U87), and investigated the effect on GBM cell adhesion and invasion. Our results demonstrate that disruption of STAT3 inhibits GBM cell's adhesion and invasion. Knockdown of STAT3 significantly increased E-cadherin but decreased N-cadherin, vascular endothelial growth factor, matrix metalloproteinase 2 and matrix metalloproteinase 9. Additionally, expression of pSTAT3(Tyr705) correlates with astrocytoma WHO classification, Karnofsky performance status scale score, tumor recurrence and survival. Furthermore, pSTAT3(Tyr705) is a significant prognostic factor in astrocytoma. In conclusion, STAT3 may affect astrocytoma invasion, expression of pSTAT3(Tyr705) is a significant prognostic factor in tumor recurrence and overall survival in astrocytoma patients. Therefore, STAT3 may provide a potential target for molecular therapy in human astrocytoma, and pSTAT3(Tyr705)could be an important biomarker for astrocytoma prognosis.


Subject(s)
Apoptosis , Biomarkers, Tumor , Brain Neoplasms , Glioblastoma , Neoplasm Proteins , STAT3 Transcription Factor , Adult , Biomarkers, Tumor/antagonists & inhibitors , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Brain Neoplasms/genetics , Brain Neoplasms/metabolism , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Cadherins/genetics , Cadherins/metabolism , Cell Adhesion/genetics , Cell Line, Tumor , Disease-Free Survival , Female , Follow-Up Studies , Glioblastoma/genetics , Glioblastoma/metabolism , Glioblastoma/mortality , Glioblastoma/pathology , Humans , Male , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Middle Aged , Neoplasm Invasiveness , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , STAT3 Transcription Factor/antagonists & inhibitors , STAT3 Transcription Factor/genetics , STAT3 Transcription Factor/metabolism , Survival Rate
8.
Neuro Oncol ; 14(8): 994-1006, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22753229

ABSTRACT

Gliomas are the leading cause of death among adults with primary brain malignancies. Treatment for malignant gliomas remains limited, and targeted therapies have been incompletely explored. In this study, we found that the protein expression of presenilin 2 (PS2) was significantly increased in glioma tissues, at least partially because of promoter demethylation. We further evaluated the biological functions of PS2 in U251 glioma cell proliferation, migration, invasion, and tumor growth in vivo by specific inhibition of PS2 using short hairpin RNA (shRNA). We found that PS2 depletion inhibited glioma cell growth as the result of inhibited proliferation and induced apoptosis. PS2 depletion also decreased the invasive capability of glioma cells and anchorage-independent colony formation in soft agar. Moreover, suppression of PS2 expression significantly impaired the growth of glioma xenografts in nude mice. Finally, the decrease in glioma cell growth caused by PS2 depletion seems to involve Nrg1/ErbB signaling. In summary, our data highlight the use of RNA interference (RNAi) as a tool to better understand the molecular basis of PS2 in glioma progression and to uncover new targets for the treatment of glioma.


Subject(s)
Brain Neoplasms/metabolism , Glioma/metabolism , Presenilin-2/metabolism , RNA, Small Interfering/genetics , Signal Transduction , Animals , Blotting, Western , Brain Neoplasms/pathology , Cell Proliferation , Female , Flow Cytometry , Gene Expression Regulation, Neoplastic/physiology , Glioma/pathology , Humans , Immunohistochemistry , Mice , Mice, Nude , Neoplasm Invasiveness/pathology , Neuregulin-1/metabolism , Polymerase Chain Reaction , Presenilin-2/genetics , Receptor, ErbB-2/metabolism , Transfection
9.
J Neurosci Res ; 88(12): 2747-54, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20648659

ABSTRACT

Urokinase-type plasminogen activator receptor (uPAR) is a glycosyl phosphatidylinositol-anchored protein involved in cell adhesion, proliferation, differentiation, migration, invasion, and tissue repair and remodeling. Our aim was to investigate uPAR expression in the frontal cortex of patients with intractable frontal lobe epilepsy and to explore the possible role of uPAR in intractable epilepsy. Tissue samples were obtained from the frontal cortex of 25 patients who had undergone surgery for intractable epilepsy and 15 histologically normal frontal cortex tissues from patients with orbital frontal lobe severe contusion (the control group). The frontal cortex expression of uPAR was studied by Western blot and immnohistochemistry. Double immunofluorescence was used to determine the expression of uPAR in astrocytes, microglia, and neurons. The normal frontal cortex uPAR protein level was shown to be low. In the brain tissue of patients with intractable epilepsy, the expression of uPAR protein increased dramatically. Based on the results of double immunofluorescence, many uPAR-positive cells are colocalized with the cell soma of NeuN-positive neurons, whereas only a few GFAP- and CD11b-positive cells colocalized with uPAR staining. These findings provide new information pertaining to the epileptogenesis of intractable epilepsy and suggest that increased expression of uPAR in human brain may be associated with human intractable epilepsy.


Subject(s)
Epilepsy/genetics , Epilepsy/metabolism , Frontal Lobe/metabolism , Receptors, Urokinase Plasminogen Activator/genetics , Adolescent , Adult , Biomarkers/metabolism , Brain Chemistry/genetics , Child , Child, Preschool , Epilepsy/pathology , Female , Frontal Lobe/pathology , Frontal Lobe/surgery , Humans , Male , Receptors, Urokinase Plasminogen Activator/biosynthesis , Young Adult
10.
DNA Cell Biol ; 28(10): 493-9, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19622038

ABSTRACT

Toll-like receptors (TLRs) initiate and maintain host defenses. These receptors play important roles in innate immunity and in various diseases. Different TLRs bind to diverse ligands that trigger distinct protein expression patterns. Few studies have focused on the interaction between different TLRs. We found that TLR2 priming downregulates TLR4 transcription, and expression of TLR4 activation induced major histocompatibility complex II (MHC II), adhesion molecule intercellular adhesion molecule-1 (ICAM-1), phagocytosis marker CD11b/CD18, and Fcgamma receptor (FcgammaR) expression. In contrast, TLR4 priming increases TLR2 transcription and expression. In addition, TLR4 priming increases secretion of certain proinflammatory mediators. Expression of costimulatory molecules CD80/CD86 increases with TLR2 or TLR4 activation sequences. Our results reveal that TLR2/TLR4 activation may determine disease pathogenesis and prognosis.


Subject(s)
Microglia/physiology , Toll-Like Receptor 2/physiology , Toll-Like Receptor 4/physiology , Adult , Base Sequence , CD11b Antigen/biosynthesis , CD18 Antigens/biosynthesis , DNA Primers , Down-Regulation , Electrophoretic Mobility Shift Assay , Flow Cytometry , Histocompatibility Antigens Class II/biosynthesis , Humans , Intercellular Adhesion Molecule-1/biosynthesis , Phenotype , Promoter Regions, Genetic , Receptors, IgG/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Toll-Like Receptor 2/chemistry , Toll-Like Receptor 2/genetics , Toll-Like Receptor 4/chemistry , Toll-Like Receptor 4/genetics
11.
Lab Invest ; 89(6): 717-25, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19290007

ABSTRACT

Abnormalities in the signal transducer and activator of transcription (STAT) pathway are involved in the oncogenesis of several cancers. However, the mechanism by which dysregulated STAT5 signaling contributes to the progression of human colorectal cancer (CRC) has not been elucidated. To investigate the role of STAT5 in CRC progression, we depleted STAT5 with a small interfering RNA (siRNA). Our results demonstrate that STAT5 is involved in CRC cell growth, cell cycle progression, invasion and migration through regulation of gene expression, such as Bcl-2, p16(ink4a), p21(waf1/cip1), p27(kip1), E-cadherin, the focal adhesion kinase (FAK), vascular endothelial growth factor (VEGF) and matrix metalloproteinases. In addition, immunohistochemical staining reveals upregulation of STAT5 during CRC tumorigenesis. Moreover, phospho-STAT5 (pSTAT5) is predominantly localized in the cytoplasm of adenomas cells and colon adenocarcinoma cells, but primarily presented in the nucleus of normal colonic epithelium cells. Thus, pSTAT5 protein is shuttled from the nucleus to the cytoplasm in the oncogenesis of CRC, suggesting that activated STAT5 may also have cytoplasmic functions. In support of this hypothesis, we found that STAT5 formed a complex with p44/42 MAPK and SAPK/JNK in CRC cells, suggesting cross talk between STAT5 signaling and the MAPK pathway in the development of human CRC. Our findings illustrate the biological significance of STAT5 signaling in CRC progression, and provide novel evidence that intervention in STAT5 signaling may have potential therapeutic value in the prevention of human colorectal cancer.


Subject(s)
Cell Movement/physiology , Colorectal Neoplasms/pathology , G1 Phase/physiology , STAT5 Transcription Factor/physiology , Apoptosis/physiology , Cell Cycle , Cell Line, Tumor , Cell Nucleus/metabolism , Cell Survival/physiology , Cell Transformation, Neoplastic , Colorectal Neoplasms/metabolism , Cytoplasm/metabolism , Gene Expression Regulation, Neoplastic , Humans , MAP Kinase Signaling System/physiology , Neoplasm Invasiveness , STAT5 Transcription Factor/antagonists & inhibitors , Signal Transduction
12.
Cancer Lett ; 273(1): 164-71, 2009 Jan 08.
Article in English | MEDLINE | ID: mdl-18793823

ABSTRACT

Abnormalities in the signal transducer and activator of transcription 5 (STAT5) signaling are involved in the oncogenesis of several cancers. However, previous studies have not elucidated clear and distinct roles for each STAT5 gene in cancers. To investigate the role of STAT5a, -5b isoforms in human glioblastoma multiforme (GBM) progression, we depleted each STAT5 isoforms with siRNA. Our results demonstrate that STAT5b is involved in GBM cell growth, cell cycle progression, invasion and migration through regulation of gene expression, such as Bcl-2, p21(waf1/cip1), p27(kip1), FAK and VEGF. Moreover, immunohistochemical staining reveals that cytoplasm staining of STAT5b is markedly increased in GBM (57.1%) compared with that in normal cortex (22.2%) and diffuse astrocytoma (27.3%), suggesting that STAT5b could have important implications in astrocytoma biology. Therefore, our findings illustrate the biological significance of STAT5b in GBM progression, and provide novel evidence that STAT5b may serve as a therapeutic target in the prevention of human glioblastoma multiforme.


Subject(s)
Drug Delivery Systems , G1 Phase/drug effects , Gene Expression Regulation, Neoplastic , Glioblastoma/drug therapy , RNA, Small Interfering/pharmacology , STAT5 Transcription Factor/antagonists & inhibitors , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival , Glioblastoma/physiopathology , Humans , Immunohistochemistry , Protein Isoforms/antagonists & inhibitors , Reverse Transcriptase Polymerase Chain Reaction
13.
J Cell Mol Med ; 13(9B): 3668-79, 2009 Sep.
Article in English | MEDLINE | ID: mdl-20196786

ABSTRACT

DNA methyltransferase inhibitors (MTIs) have recently emerged as promising chemotherapeutic or preventive agents for cancer, despite their poorly characterized mechanisms of action. The present study shows that DNA methylation is integral to the regulation of SH2-containing protein tyrosine phosphatase 1 (SHP1) expression, but not for regulation of suppressors of cytokine signalling (SOCS)1 or SOCS3 in colorectal cancer (CRC) cells. SHP1 expression correlates with down-regulation of Janus kinase/signal transducers and activators of transcription (JAK2/STAT3/STAT5) signalling, which is mediated in part by tyrosine dephosphorylation events and modulation of the proteasome pathway. Up-regulation of SHP1 expression was achieved using a DNA MTI, 5-aza-2'-deoxycytidine (5-aza-dc), which also generated significant down-regulation of JAK2/STAT3/STAT5 signalling. We demonstrate that 5-aza-dc suppresses growth of CRC cells, and induces G2 cell cycle arrest and apoptosis through regulation of downstream targets of JAK2/STAT3/STAT5 signalling including Bcl-2, p16(ink4a), p21(waf1/cip1) and p27(kip1). Although 5-aza-dc did not significantly inhibit cell invasion, 5-aza-dc did down-regulate expression of focal adhesion kinase and vascular endothelial growth factor in CRC cells. Our results demonstrate that 5-aza-dc can induce SHP1 expression and inhibit JAK2/STAT3/STAT5 signalling. This study represents the first evidence towards establishing a mechanistic link between inhibition of JAK2/STAT3/STAT5 signalling and the anticancer action of 5-aza-dc in CRC cells that may lead to the use of MTIs as a therapeutic intervention for human colorectal cancer.


Subject(s)
Apoptosis , Cell Cycle/drug effects , DNA Modification Methylases/antagonists & inhibitors , Gene Expression Regulation, Enzymologic , Janus Kinase 2/metabolism , Protein Tyrosine Phosphatase, Non-Receptor Type 6/metabolism , STAT3 Transcription Factor/metabolism , STAT5 Transcription Factor/metabolism , Azacitidine/analogs & derivatives , Azacitidine/pharmacology , Cell Line, Tumor , Colorectal Neoplasms/metabolism , DNA Methylation , Decitabine , G2 Phase , Humans , Transcription, Genetic
14.
Stereotact Funct Neurosurg ; 86(4): 237-44, 2008.
Article in English | MEDLINE | ID: mdl-18477840

ABSTRACT

OBJECTIVE: The goal of the present study was to evaluate the effects of bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) on olfaction in patients with Parkinson's disease (PD). METHODS: 15 patients suffering from sporadic PD-related dysosmia were implanted with bilateral electrodes aimed at the STN. One week before the surgery, odor detection threshold (DT) and identification threshold (IT) were evaluated in all patients using the 'five odor olfactory detection arrays' in both medication-off and medication-on conditions. 15 healthy age-matched controls also received the same olfactory evaluation. Patient evaluations were repeated at 6 and 12 months postoperatively in a medication-off/stimulator-on or medication-off/stimulator-off condition. Odor DT and IT scores were compared pre- and postoperatively, as well as between the medication-off/stimulator-on or -off conditions. RESULTS: The motor symptoms of all 15 PD patients, including rigidity, tremor, bradykinesia, postural instability, and gait were significantly improved after stimulator implantation. The UPDRS motor (UPDRS III) scores decreased significantly in the medication-off/stimulator-on condition (p < 0.01). The odor DT and IT scores of PD patients were higher than those of healthy controls (p < 0.01). In the medication-off/stimulator-off condition, there was no significant difference in the odor DT and IT scores in PD patients pre- vs. postoperatively (p > 0.05). Notably, there were no significant alterations to DT scores in the stimulator-on and -off conditions at the 6- and 12-month follow-up (p > 0.05), whereas IT scores were significantly improved in the stimulation-on relative to the stimulation-off condition at the 6- and 12-month follow-up. CONCLUSIONS: STN DBS can significantly improve olfactory cognitive function in PD patients. The possible mechanisms include an improvement in striatal metabolism and neuronal activity in the orbitofrontal cortex mediated by STN DBS, as well as increased glucose metabolism in the striatum, midbrain, cingulate gyrus, and motor and higher-order somatosensory association cortices.


Subject(s)
Deep Brain Stimulation , Parkinson Disease/physiopathology , Parkinson Disease/therapy , Smell/physiology , Subthalamic Nucleus/physiology , Adult , Aged , Deep Brain Stimulation/methods , Female , Humans , Male , Middle Aged , Odorants , Treatment Outcome
15.
Neoplasia ; 10(3): 287-97, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18320073

ABSTRACT

Abnormalities in the STAT3 pathway are involved in the oncogenesis of several cancers. However, the mechanism by which dysregulated STAT3 signaling contributes to the progression of human colorectal cancer (CRC) has not been elucidated, nor has the role of JAK, the physiological activator of STAT3, been evaluated. To investigate the role of both JAK and STAT3 in CRC progression, we inhibited JAK with AG490 and depleted STAT3 with a SiRNA. Our results demonstrate that STAT3 and both JAK1 and 2 are involved in CRC cell growth, survival, invasion, and migration through regulation of gene expression, such as Bcl-2, p1(6ink4a), p21(waf1/cip1), p27(kip1), E-cadherin, VEGF, and MMPs. Importantly, the FAK is not required for STAT3-mediated regulation, but does function downstream of JAK. In addition, our data show that proteasome-mediated proteolysis promotes dephosphorylation of the JAK2, and consequently, negatively regulates STAT3 signaling in CRC. Moreover, immunohistochemical staining reveals that nuclear staining of phospho-STAT3 mostly presents in adenomas and adenocarcinomas, and a positive correlation is found between phospho-JAK2 immunoreactivity and the differentiation of colorectal adenocarcinomas. Therefore, our findings illustrate the biologic significance of JAK1, 2/STAT3 signaling in CRC progression and provide novel evidence that the JAK/STAT3 pathway may be a new potential target for therapy of CRC.


Subject(s)
Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Janus Kinase 1/antagonists & inhibitors , Janus Kinase 1/physiology , STAT3 Transcription Factor/antagonists & inhibitors , STAT3 Transcription Factor/physiology , Apoptosis , Cadherins/metabolism , Cell Cycle/drug effects , Colorectal Neoplasms/drug therapy , Cysteine Proteinase Inhibitors/pharmacology , Down-Regulation , Focal Adhesion Kinase 1/metabolism , Humans , Janus Kinase 2/metabolism , Leupeptins/pharmacology , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Neoplasm Invasiveness , Protein Kinase Inhibitors/pharmacology , RNA, Small Interfering/pharmacology , Signal Transduction/drug effects , Tyrphostins/pharmacology , Vascular Endothelial Growth Factor A/metabolism
16.
Mol Med ; 12(9-10): 229-36, 2006.
Article in English | MEDLINE | ID: mdl-17225871

ABSTRACT

A new chimeric IgG1 antibody hCAb which could be specifically directed against a cell surface-associated glycoprotein of colorectal cancer cells was prepared by genetic engineering technology in our lab. In this study, we explored the potential therapeutic mechanisms and described the evaluation of hCAb directed against colorectal cancer. The standard 51Cr release assay showed that like many other clinically validated IgG1 monoclonal antibodies, hCAb primarily acts by antibody-dependent cell-mediated cytotoxicity (ADCC). The maximal cell lysis of ADCC induced by hCAb was over 50% in the presence of peripheral blood mononuclear cells (PBMCs). Moreover, in vivo studies showed potent antitumor effects in nude mice with SW480 and Hce-8693 tumor xenografts. The treatment with hCAb induced a dramatic reduction (over 70%) in tumor volume in comparison to untreated control group. Furthermore, during the period of treatment, the animals treated by hCAb did not show signs of wasting or other visible signs of toxicity. No obvious tissue damage in vital organs was detected. The chimeric antibody hCAb may be a promising candidate in the treatment of human colorectal cancer. This study can provide a reference for the potential application of hCAb in clinical trial.


Subject(s)
Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/therapeutic use , Antigens, Neoplasm/immunology , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/immunology , Animals , Antibodies, Monoclonal/isolation & purification , Antibody Affinity/immunology , Antibody Specificity/immunology , Antibody-Dependent Cell Cytotoxicity/immunology , Blood Platelets/cytology , Blotting, Western , Cell Count , Cell Line, Tumor , Chromatography, High Pressure Liquid , Female , Flow Cytometry , Humans , Kinetics , Leukocytes/cytology , Mice , Mice, Nude , Recombinant Fusion Proteins/immunology , Recombinant Fusion Proteins/isolation & purification , Recombinant Fusion Proteins/therapeutic use , Xenograft Model Antitumor Assays
17.
Biotechnol Lett ; 27(21): 1713-7, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16247680

ABSTRACT

A dicistronic expression vector was constructed for Chinese hamster ovary (CHO) cells that produce both selectable marker-DHFR (dihydrofolate reductase) gene and recombinant antibody cDNA from a single primary transcript via differential splicing. The vector was derived from a pDHL vector and contained the human constant region cDNA so that any human-mouse chimeric antibodies could be expressed. The expression vector produced stable CHO cell clones that secreted nearly double the amount of chimeric antibodies than produced by conventional expression approaches, where the DHFR gene and relevant cDNA are controlled by separate transcription cassettes. Clones with increased expression of interested genes can be efficiently generated by selection in medium containing a gradually increasing amount of methotrexate. The dicistronic expression system using incomplete splicing DHFR gene strategy thus provides a convenient, high-level, and rapid expression of chimeric antibodies.


Subject(s)
Antibodies, Monoclonal/biosynthesis , Gene Expression , Genes , Genetic Vectors , Recombinant Fusion Proteins/biosynthesis , Tetrahydrofolate Dehydrogenase/biosynthesis , Animals , Antibodies, Monoclonal/genetics , CHO Cells , Cricetinae , Recombinant Fusion Proteins/genetics , Tetrahydrofolate Dehydrogenase/genetics
18.
Cancer Biol Ther ; 4(7): 759-62, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15970688

ABSTRACT

Basigin/CD147, also named extracelluar matrix metalloproteinase inducer (EMMPRIN), has been implicated in playing very important roles in several aspects of tumor progression. In this study, we examined the inhibitory effects of antisense RNA of CD147 on invasion and angiogenesis of human glioblastoma U251 cells in vitro. The U251 cell line was transfected by a plasmid containing antisense CD147 cDNA. Gelatin zymography was used to determine the effect on reducing secretions of MMP-2 and MMP-9 of the transfected cells. Boyden chamber was employed to test the invasion of U251 cells in vitro. We found that downregulation of CD147 resulted in reducing secretions of MMP-2, MMP-9, and VEGF. Moreover, the invasion of stable antisense transfectants was inhibited. Wound-induced migration assay also showed decreased migration in stable antisense transfectants compare to parental- and empty vector-transfected cells. Taken together, these results provide evidence that invasion of human glioblastoma cells can be inhibited by antisense RNA of CD147. Basigin/CD147 may be used as a potential target of drugs for anti-invasion and metastasis of human glioblastoma cells.


Subject(s)
Basigin/physiology , Glioblastoma/prevention & control , Neovascularization, Pathologic/prevention & control , RNA, Antisense/pharmacology , Blotting, Western , Cell Movement/drug effects , Down-Regulation , Enzyme-Linked Immunosorbent Assay , Gene Expression/drug effects , Glioblastoma/metabolism , Glioblastoma/pathology , Humans , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Neoplasm Invasiveness , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , Transfection , Tumor Cells, Cultured , Vascular Endothelial Growth Factor A/metabolism , Wounds and Injuries/pathology
19.
Stereotact Funct Neurosurg ; 81(1-4): 96-104, 2003.
Article in English | MEDLINE | ID: mdl-14742971

ABSTRACT

The aim of this study was to explore a new way of treating drug addiction by ablating the nucleus accumbens (NAC), which has a close relationship with drug-induced psychological dependence, using stereotactic surgery, blocking the mesocorticolimbic dopamine circuit, alleviating craving for drugs and lowering the relapse rate after detoxification. On the basis of animal experiments, stereotactic surgery was performed in 28 patients by making a lesion in the NAC bilaterally to treat opiate drug dependence. Indications, the criterion of therapeutic effect, treatment process and the therapeutic and safety evaluation index of the surgery were formulated particularly. The mean follow-up period was 15 months. Relapse has not occurred in 11 cases up till now. Drug-free time in these patients has been more than half a year in 4 cases (more than a year in 3 cases), and less than half a year in 7 cases. Relapse occurred in 15 cases after surgery. Drug-free time in these patients was more than half a year in 3 cases, between 1 month and half a year in 10 cases and less than 1 month in 2 cases. The therapeutic effect was excellent in 7 cases (26.9%), good in 10 cases (38.5%) and poor in 2 cases (7.7%). Another 7 cases were still under investigation at the time of writing. Relapse rates after surgery were 7.7, 38.5 and 57.5% within 1 month, between 1 month and half a year and after more than half a year, respectively. There were no common complications of surgery such as intracranial hematoma or infection in these patients after operation. Character type was changed slightly in 2 cases, and 4 cases suffered temporary memory loss, which did not affect their daily lives and learning function. They all recovered within 1 month. There were different degrees of effectiveness of treating drug addicts' psychological dependence by making lesions in the NAC bilaterally with stereotactic surgery. No particular complications occurred. The operation is safe and feasible. The mean follow-up time in this study was 15 months. The effectiveness was satisfactory. The relapse rate of drug addicts after detoxification was clearly reduced.


Subject(s)
Nucleus Accumbens/surgery , Opioid-Related Disorders/surgery , Follow-Up Studies , Humans , Neurosurgical Procedures , Opioid-Related Disorders/psychology , Recurrence , Stereotaxic Techniques , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...